ELVNEnliven Therapeutics, Inc.
$40.98+116% 1Y
$40.98
$15.1452 weeks$61.15
ELVN as reported
- Net income
- −$106M
Net income · +5.7% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$67M
Free cash flow · −5.3% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.67
EPS · −17% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$106M | +5.7% | Q2 2026 |
| EPS | −$1.67 | −17% | Q2 2026 |
| ROE | −19% | n/a | Q2 2026 |
| ROA | −19% | n/a | Q2 2026 |
| Free cash flow | −$67M | −5.3% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Enliven Therapeutics, Inc. (ELVN) · Net incomeNet incomeEnliven Therapeutics, Inc. (ELVN)
On our screens:Most shorted stocks